Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Researchers identify a cause of L-DOPA–induced dyskinesia in Parkinson’s disease
Key clinical point: Understanding the chemical responsible for treatment-related dyskinesia may help improve therapy for Parkinson’s disease.
Major finding: RasGRP1 directs the development of L-DOPA–induced dyskinesia in Parkinson’s disease.
Study details: A prospective study of 55 mouse models of Parkinson’s disease.
Disclosures: The study was supported by grants from the National Institutes of Health. The authors reported no conflicts of interest.
Citation:
Eshraghi M et al. Sci Adv. 2020;6:eaaz7001.